Magnesium suppresses GSK-3β with no effect on PP2A in the hippocampus of ICV-STZ-treated rats.

Abstract

<p>Rats were divided into sham-operated control (Con), sham-operated plus 100 mg/kg magnesium control (Mg), STZ ICV (STZ) or STZ ICV plus 100 mg/kg magnesium (STZ+Mg) groups and treated as shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0108645#pone-0108645-g001" target="_blank">Figure 1A</a>. The total GSK-3β, GSK-3β (Ser9), GSK-3β (Tyr216), total PP2A and PP2A (pY307) levels in whole hippocampus extracts were measured using Western blotting (A, C) and quantitative analysis (B, D). The level of p-GSK-3β (Ser9) was significantly decreased in ICV-STZ-treated rats, and magnesium supplementation restored the levels. No alterations in total GSK-3β, p-GSK-3β (Y216), total PP2A and PP2A (pY307) levels were detected in these groups. Data were presented as means ± SD. *<i>P</i><0.05 versus the control group, <i>#P</i><0.05 versus the STZ group.</p